Development of a Gastric Cancer Screening Intervention for H. Pylori Carriers Based on the Health Belief Model (HBM-GCS)
Development of a Gastric Cancer Screening Intervention Program for Helicobacter Pylori Carriers Based on the Health Belief Model
Gastric cancer (GC) remains a major global public health challenge. It often causes no obvious symptoms in the early stage, so most patients are diagnosed at an advanced stage. This highlights the importance of gastric cancer screening among high-risk populations to achieve early detection and improve survival outcomes. People infected with Helicobacter pylori (Hp) are at high risk of gastric cancer. Hp is one of the most common bacterial infections worldwide. It initiates carcinogenesis by triggering chronic atrophic gastritis and intestinal metaplasia, known as the Correa cascade. However, the acceptance of gastric cancer screening among Hp-infected individuals is still unsatisfactory. To our knowledge, there are few theory-based interventions designed to help Hp-infected people make decisions about gastric cancer screening and increase screening uptake. Therefore, based on our previous systematic review, this study aims to develop a health promotion program to improve gastric cancer screening participation among Hp-infected individuals in mainland China. Participants in the intervention group will receive a comprehensive health promotion program, including a 30-minute health education session. They will receive a 15-minute telephone follow-up with gastric cancer screening information in week 2, and additional 10-minute telephone follow-ups at weeks 2, 4, and 6 to help participants identify and overcome barriers to gastric cancer screening. Participants in the control group will receive routine care. Data on gastric cancer screening participation will be collected at the end of the intervention. Findings from this study will be valuable for gastric cancer prevention among people with Hp infection.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Participants in the intervention group will receive the following multi-session health promotion intervention. The details are as follows.
Screening benefit construction (30 min). In the first week, education will be delivered through face-to-face for the following information:
(1) Hp infection and increased gastric cancer risk; (2) gastric cancer screening recommendations regarding eligibility, available screening tests, and recommended screening intervals; (3) pros/advantages of undergoing gastric cancer screening; (4) cons/disadvantages or uncertainties of undergoing gastric cancer screening; (5) implications of positive screening results; and (6) health costs and service information. The educational material will be presented in a self-made manual, which will be explained and distributed to each participant.
Screening barrier navigation (15 min). It will be conducted in the second week by telephone. The nurse counsellor will help participants resolve individual barriers related to gastric cancer screening. The tailored content includes:
(1) Q&A about gastroscopy screening; (2) gastroscopy appointment procedure; (3) hospital and transportation information; (4) medical insurance consultation; (5) precautions for the examination.
Screening self-efficacy reinforcement (10 min each). At the fourth and sixth weeks, the nurse counsellor will work with participants through a telephone-based way (with WeChat as an auxiliary tool) to strengthen confidence in completing gastric cancer screening, in which participants will: (1) track the progress of screening arrangements; (2) receive home health guidance while waiting for the screening examination.
Participants in the control group will receive routine health care for Hp infection without this theory-based gastric cancer screening promotion program.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Mengyao Gao, MN
- Telefonnummer: (86)15870682367
- E-post: 15870682367@163.com
Studer Kontakt Backup
- Navn: Caixia Li, PhD
- Telefonnummer: (86) 19867712062
- E-post: licx23@mail.sysu.edu.cn
Studiesteder
-
-
Guangdong
-
Shenzhen, Guangdong, Kina, 518000
- The University of Hong Kong-Shenzhen Hospital
-
Ta kontakt med:
- Mengyao Gao, MN
- Telefonnummer: (86)15870682367
- E-post: 15870682367@163.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Aged between 45 and 74 years.
- Diagnosed with *Helicobacter pylori* infection confirmed by urea breath test (UBT), serological antibody test, or stool antigen test.
- Have adequate communication, reading, and comprehension ability.
- Provide informed consent, voluntarily participate in the study, and cooperate with all study procedures.
Exclusion Criteria:
-
1. Previously diagnosed with gastric cancer or other advanced malignant tumors. 2. Cognitive impairment, severe hepatic or renal insufficiency, psychiatric disorders, or severe physical illness that prevents cooperation with the interview.
3. Pregnant or breastfeeding women.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Screening
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Experimental: Health Belief Model-based intervention group
Provide education, tailored information, barrier counseling, and decision support regarding gastric cancer screening for Helicobacter pylori-infected individuals. |
Provide health education, tailored information, barrier counseling and follow-up regarding gastric cancer screening for Helicobacter pylori-infected individuals. |
|
Annen: Control group
Usual care provided by the hospital, including one-page written education material on gastroscopy. |
Usual care provided by the hospital, including one-page written education material on gastroscopy. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Gastric cancer screening intention
Tidsramme: Immediately and 6 weeks after intervention
|
Participants' behavioral tendency and psychological readiness to actively seek and undergo gastroscopy within the next 5 years. |
Immediately and 6 weeks after intervention
|
|
Gastroscopy completion rate
Tidsramme: 6 weeks after intervention
|
An objective outcome is defined as the number of participants who complete gastroscopy after intervention. The gastroscopy completion rates among Helicobacter pylori-infected participants in the two groups will be compared, serving as the key quantitative indicator to evaluate whether the intervention improves actual screening behavior. |
6 weeks after intervention
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Gastric cancer screening knowledge score
Tidsramme: Immediately and 6 weeks after intervention
|
Assessed with knowledge items from Huang et al. (2022). The scale measures participants' knowledge of gastric cancer risk factors and warning symptoms, consisting of 24 items on risk factors and 14 items on warning symptoms. |
Immediately and 6 weeks after intervention
|
|
Total score of the Health Belief Model (HBM) questionnaire for gastric cancer screening
Tidsramme: Immediately and 6 weeks after intervention
|
This subscale was developed based on the five-dimensional HBM framework proposed by Becker (1974), including perceived susceptibility to gastric cancer (3 items), perceived severity (3 items), perceived benefits of gastric cancer screening (2 items), perceived barriers to screening (5 items), and cues to action (3 items). The total score of the five dimensions is calculated. |
Immediately and 6 weeks after intervention
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Mengyao Gao, MN, Kiang Wu Nursing College of Macau(KWNC)
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- Gastric Cancer Screening
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .